Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 2001 May 1;355(Pt 3):639–645. doi: 10.1042/bj3550639

Plasmin-dependent elimination of the growth-factor-like domain in urokinase causes its rapid cellular uptake and degradation.

A Poliakov 1, V Tkachuk 1, T Ovchinnikova 1, N Potapenko 1, S Bagryantsev 1, V Stepanova 1
PMCID: PMC1221778  PMID: 11311125

Abstract

Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) act in concert to mediate pericellular proteolysis and to stimulate intracellular signalling responsible for cell migration and proliferation. uPA is composed of three domains, a proteolytic domain (PD), a kringle domain (KD) and a growth-factor-like domain (GFD), the last of which mediates the interaction with uPAR. We demonstrate that uPA, associated with the surface of U937 cells, undergoes plasmin-mediated cleavage of the Lys(46)-Ser(47) bond with elimination of the GFD. Using recombinant forms of uPA, we show that a uPA variant lacking the GFD (r-uPADeltaGFD) and unable to associate with uPAR is rapidly cleared from the cell surface. Binding and internalization of r-uPADeltaGFD are markedly decreased in the presence of 39 kDa receptor-associated protein (RAP), the antagonist of several endocytic receptors of the low-density lipoprotein receptor family, suggesting that this protein clearance pathway is used for r-uPADeltaGFD. In contrast with rapidly internalized r-uPADeltaGFD, the intact recombinant single-chain urokinase with wild-type structure (r-uPAwt) bound to uPAR is retained on the cell surface. Soluble uPAR protects uPA from cleavage by plasmin that results in the elimination of GFD, suggesting that uPAR might protect cell-bound urokinase from plasmin-mediated cleavage between the GFD and KD and subsequent degradation.

Full Text

The Full Text of this article is available as a PDF (180.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreasen P. A., Kjøller L., Christensen L., Duffy M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997 Jul 3;72(1):1–22. doi: 10.1002/(sici)1097-0215(19970703)72:1<1::aid-ijc1>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  2. Argraves K. M., Battey F. D., MacCalman C. D., McCrae K. R., Gåfvels M., Kozarsky K. F., Chappell D. A., Strauss J. F., 3rd, Strickland D. K. The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes. J Biol Chem. 1995 Nov 3;270(44):26550–26557. doi: 10.1074/jbc.270.44.26550. [DOI] [PubMed] [Google Scholar]
  3. Behrendt N., Rønne E., Danø K. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol Chem Hoppe Seyler. 1995 May;376(5):269–279. [PubMed] [Google Scholar]
  4. Bhat G. J., Gunaje J. J., Idell S. Urokinase-type plasminogen activator induces tyrosine phosphorylation of a 78-kDa protein in H-157 cells. Am J Physiol. 1999 Aug;277(2 Pt 1):L301–L309. doi: 10.1152/ajplung.1999.277.2.L301. [DOI] [PubMed] [Google Scholar]
  5. Blasi F., Vassalli J. D., Danø K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol. 1987 Apr;104(4):801–804. doi: 10.1083/jcb.104.4.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Carmeliet P., Collen D. Vascular development and disorders: molecular analysis and pathogenic insights. Kidney Int. 1998 Jun;53(6):1519–1549. doi: 10.1046/j.1523-1755.1998.00936.x. [DOI] [PubMed] [Google Scholar]
  7. Carriero M. V., Del Vecchio S., Capozzoli M., Franco P., Fontana L., Zannetti A., Botti G., D'Aiuto G., Salvatore M., Stoppelli M. P. Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res. 1999 Oct 15;59(20):5307–5314. [PubMed] [Google Scholar]
  8. Cavallaro U., Wu Z., Di Palo A., Montesano R., Pepper M. S., Maier J. A., Soria M. R. FGF-2 stimulates migration of Kaposi's sarcoma-like vascular cells by HGF-dependent relocalization of the urokinase receptor. FASEB J. 1998 Aug;12(11):1027–1034. doi: 10.1096/fasebj.12.11.1027. [DOI] [PubMed] [Google Scholar]
  9. Chang A. W., Kuo A., Barnathan E. S., Okada S. S. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase. Arterioscler Thromb Vasc Biol. 1998 Dec;18(12):1855–1860. doi: 10.1161/01.atv.18.12.1855. [DOI] [PubMed] [Google Scholar]
  10. Christow S. P., Bychkov R., Schroeder C., Dietz R., Haller H., Dumler I., Gulba D. C. Urokinase activates calcium-dependent potassium channels in U937 cells via calcium release from intracellular stores. Eur J Biochem. 1999 Oct 1;265(1):264–272. doi: 10.1046/j.1432-1327.1999.00729.x. [DOI] [PubMed] [Google Scholar]
  11. Cubellis M. V., Wun T. C., Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J. 1990 Apr;9(4):1079–1085. doi: 10.1002/j.1460-2075.1990.tb08213.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Del Rosso M., Anichini E., Pedersen N., Blasi F., Fibbi G., Pucci M., Ruggiero M. Urokinase-urokinase receptor interaction: non-mitogenic signal transduction in human epidermal cells. Biochem Biophys Res Commun. 1993 Jan 29;190(2):347–352. doi: 10.1006/bbrc.1993.1054. [DOI] [PubMed] [Google Scholar]
  13. Dosne A. M., Dubor F., Samama M. Importance of plasminogen activator inhibitor type 1 (PAI-1) for preventing single chain urokinase plasminogen activator (scu-PA) conversion into two chain urokinase plasminogen activator (tcu-PA) in plasma in vitro. Thromb Res. 1991 Sep 1;63(5):531–539. doi: 10.1016/0049-3848(91)90178-y. [DOI] [PubMed] [Google Scholar]
  14. Dumler I., Kopmann A., Weis A., Mayboroda O. A., Wagner K., Gulba D. C., Haller H. Urokinase activates the Jak/Stat signal transduction pathway in human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 1999 Feb;19(2):290–297. doi: 10.1161/01.atv.19.2.290. [DOI] [PubMed] [Google Scholar]
  15. Eaton D. L., Scott R. W., Baker J. B. Purification of human fibroblast urokinase proenzyme and analysis of its regulation by proteases and protease nexin. J Biol Chem. 1984 May 25;259(10):6241–6247. [PubMed] [Google Scholar]
  16. Ellis V., Danø K. Plasminogen activation by receptor-bound urokinase. Semin Thromb Hemost. 1991 Jul;17(3):194–200. doi: 10.1055/s-2007-1002609. [DOI] [PubMed] [Google Scholar]
  17. Ellis V., Scully M. F., Kakkar V. V. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem. 1989 Feb 5;264(4):2185–2188. [PubMed] [Google Scholar]
  18. Herz J., Clouthier D. E., Hammer R. E. LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell. 1992 Oct 30;71(3):411–421. doi: 10.1016/0092-8674(92)90511-a. [DOI] [PubMed] [Google Scholar]
  19. Higazi A. A., Mazar A., Wang J., Reilly R., Henkin J., Kniss D., Cines D. Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1. Blood. 1996 May 1;87(9):3545–3549. [PubMed] [Google Scholar]
  20. Jensen P. H., Christensen E. I., Ebbesen P., Gliemann J., Andreasen P. A. Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells. Cell Regul. 1990 Dec;1(13):1043–1056. doi: 10.1091/mbc.1.13.1043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kasai S., Arimura H., Nishida M., Suyama T. Proteolytic cleavage of single-chain pro-urokinase induces conformational change which follows activation of the zymogen and reduction of its high affinity for fibrin. J Biol Chem. 1985 Oct 5;260(22):12377–12381. [PubMed] [Google Scholar]
  22. Kindzelskii A. L., Eszes M. M., Todd R. F., 3rd, Petty H. R. Proximity oscillations of complement type 4 (alphaX beta2) and urokinase receptors on migrating neutrophils. Biophys J. 1997 Oct;73(4):1777–1784. doi: 10.1016/S0006-3495(97)78208-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kirchheimer J. C., Remold H. G. Functional characteristics of receptor-bound urokinase on human monocytes: catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitors. Blood. 1989 Sep;74(4):1396–1402. [PubMed] [Google Scholar]
  24. Kobayashi H., Gotoh J., Hirashima Y., Fujie M., Sugino D., Terao T. Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. J Biol Chem. 1995 Apr 7;270(14):8361–8366. doi: 10.1074/jbc.270.14.8361. [DOI] [PubMed] [Google Scholar]
  25. Longstaff C., Merton R. E., Fabregas P., Felez J. Characterization of cell-associated plasminogen activation catalyzed by urokinase-type plasminogen activator, but independent of urokinase receptor (uPAR, CD87). Blood. 1999 Jun 1;93(11):3839–3846. [PubMed] [Google Scholar]
  26. May A. E., Kanse S. M., Lund L. R., Gisler R. H., Imhof B. A., Preissner K. T. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med. 1998 Sep 21;188(6):1029–1037. doi: 10.1084/jem.188.6.1029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Mukhina S., Stepanova V., Traktouev D., Poliakov A., Beabealashvilly R., Gursky Y., Minashkin M., Shevelev A., Tkachuk V. The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis. J Biol Chem. 2000 Jun 2;275(22):16450–16458. doi: 10.1074/jbc.M909080199. [DOI] [PubMed] [Google Scholar]
  28. Nguyen D. H., Hussaini I. M., Gonias S. L. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem. 1998 Apr 3;273(14):8502–8507. doi: 10.1074/jbc.273.14.8502. [DOI] [PubMed] [Google Scholar]
  29. Nykjaer A., Kjøller L., Cohen R. L., Lawrence D. A., Garni-Wagner B. A., Todd R. F., 3rd, van Zonneveld A. J., Gliemann J., Andreasen P. A. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor. J Biol Chem. 1994 Oct 14;269(41):25668–25676. [PubMed] [Google Scholar]
  30. Nykjaer A., Petersen C. M., Møller B., Jensen P. H., Moestrup S. K., Holtet T. L., Etzerodt M., Thøgersen H. C., Munch M., Andreasen P. A. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem. 1992 Jul 25;267(21):14543–14546. [PubMed] [Google Scholar]
  31. Okada S. S., Tomaszewski J. E., Barnathan E. S. Migrating vascular smooth muscle cells polarize cell surface urokinase receptors after injury in vitro. Exp Cell Res. 1995 Mar;217(1):180–187. doi: 10.1006/excr.1995.1077. [DOI] [PubMed] [Google Scholar]
  32. Petersen L. C., Lund L. R., Nielsen L. S., Danø K., Skriver L. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem. 1988 Aug 15;263(23):11189–11195. [PubMed] [Google Scholar]
  33. Poliakov A. A., Mukhina S. A., Traktouev D. O., Bibilashvily R. S., Gursky Y. G., Minashkin M. M., Stepanova V. V., Tkachuk V. A. Chemotactic effect of urokinase plasminogen activator: a major role for mechanisms independent of its proteolytic or growth factor domains. J Recept Signal Transduct Res. 1999 Nov;19(6):939–951. doi: 10.3109/10799899909038433. [DOI] [PubMed] [Google Scholar]
  34. Pöllänen J., Saksela O., Salonen E. M., Andreasen P., Nielsen L., Danø K., Vaheri A. Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol. 1987 Apr;104(4):1085–1096. doi: 10.1083/jcb.104.4.1085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Reinartz J., Schaefer B., Bechtel M. J., Kramer M. D. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator. Exp Cell Res. 1996 Feb 25;223(1):91–101. doi: 10.1006/excr.1996.0061. [DOI] [PubMed] [Google Scholar]
  36. Rømer J., Lund L. R., Eriksen J., Pyke C., Kristensen P., Danø K. The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. J Invest Dermatol. 1994 Apr;102(4):519–522. doi: 10.1111/1523-1747.ep12373187. [DOI] [PubMed] [Google Scholar]
  37. Schwartz B. S. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism. J Biol Chem. 1994 Mar 18;269(11):8319–8323. [PubMed] [Google Scholar]
  38. Stephens R. W., Pöllänen J., Tapiovaara H., Leung K. C., Sim P. S., Salonen E. M., Rønne E., Behrendt N., Danø K., Vaheri A. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol. 1989 May;108(5):1987–1995. doi: 10.1083/jcb.108.5.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Stump D. C., Lijnen H. R., Collen D. Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator. J Biol Chem. 1986 Dec 25;261(36):17120–17126. [PubMed] [Google Scholar]
  40. Tapiovaara H., Stephens R. W., Vaheri A. Persistence of plasmin-mediated pro-urokinase activation on the surface of human monocytoid leukemia cells in vitro. Int J Cancer. 1993 Feb 1;53(3):499–505. doi: 10.1002/ijc.2910530324. [DOI] [PubMed] [Google Scholar]
  41. Tkachuk V., Stepanova V., Little P. J., Bobik A. Regulation and role of urokinase plasminogen activator in vascular remodelling. Clin Exp Pharmacol Physiol. 1996 Sep;23(9):759–765. doi: 10.1111/j.1440-1681.1996.tb01177.x. [DOI] [PubMed] [Google Scholar]
  42. Xue W., Mizukami I., Todd R. F., 3rd, Petty H. R. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res. 1997 May 1;57(9):1682–1689. [PubMed] [Google Scholar]
  43. Yebra M., Goretzki L., Pfeifer M., Mueller B. M. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction. Exp Cell Res. 1999 Jul 10;250(1):231–240. doi: 10.1006/excr.1999.4510. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES